Nothing you can feel tells you anything here. For a lot of people the first sign of heart disease is the heart attack itself, which is why this is worth measuring rather than waiting to notice something.
Most people have had a cholesterol panel and been told it was fine. That panel is a reasonable start and a poor finish, for two reasons. The first is that it measures the amount of cholesterol in your blood, when what damages an artery is the number of particles carrying it around, and those two do not always agree. The second is that it leaves out Lp(a), an inherited risk factor that about one adult in five has and almost nobody has been told about.
Two of the tests below fix that. The rest tell you whether the process is already underway.
You pay no more for using it. As an Amazon Associate I earn from qualifying purchases.
Last updated August 15, 2026
The best single blood test for heart risk. Every particle that can lodge in an artery wall carries exactly one ApoB, so this counts the particles rather than weighing their contents. That matters because the two can disagree, and when they do it is the particle count that tracks the risk, not the cholesterol number [1]. Disagreement is most common in people with metabolic problems, which is exactly the group a standard panel is most likely to reassure wrongly [2].
Inherited, set at birth, stable for life, and measured once ever. If it is high it raises your risk on its own, independently of everything else you can change [3]. Roughly one adult in four or five has a raised level and about one in a thousand has ever been tested [4]. There is no reason not to have this number.
Low-grade inflammation, which predicts cardiovascular events independently of cholesterol [5]. Read it as context rather than a target: it tells you whether an inflammatory process is running, and it is raised by any recent infection, so do not test while unwell.
Still worth having, both for the triglycerides and HDL, and because the ratio between them is a free read on insulin resistance. Think of it as the background against which ApoB is interpreted rather than the answer on its own.
Blood sugar damages arteries directly, and the risk starts climbing below the diabetes threshold rather than at it [6]. This is on a heart list because the two problems are the same problem seen from different angles.
The earliest sign that the metabolic side is drifting, years before HbA1c moves. If you want the fuller version of this argument, the metabolic page makes that case in full.
A focused look at the forces that actually drive heart disease: the cholesterol particles that build plaque, the inflammation that keeps it active, and the blood sugar and insulin that speed the whole process along. A sharper read than a standard cholesterol panel.
This is the panel built for exactly this question. It carries all six tests below, which is the whole list, and it costs substantially less than ordering them one at a time. Lp(a) is included as a measure-once test, so if you already know that number you will not need it again.
Want a different mix? Browse the full library, or tell us what you have noticed if you are not sure where to start.
Start with what a standard panel measures. Picture your bloodstream as a harbor: the cholesterol is cargo, and the particles carrying it are the ships. A cholesterol panel weighs the cargo. But what damages an artery is a ship running aground in the wall and staying there. The two usually track together, since more cargo means more ships, which is why LDL cholesterol works as well as it does.
But they do not always track. Ships vary in how full they are, so the same weight of cargo can mean a few full ships or many half-empty ones. When the two disagree, risk follows the number of ships [1]. That is what ApoB measures: every one of these particles carries exactly one ApoB, so counting ApoB counts the ships.
You can see the limits of that in who ends up in hospital. Across 136,905 admissions for coronary artery disease, the average LDL on arrival was about 105 mg/dL, roughly the level most people are told is fine [7]. That is not evidence that cholesterol is harmless. Its role in causing heart disease is well established [8]. It is evidence that LDL alone misses people who are at risk.
The same study hints at why. More than half arrived with a low HDL, which is the signature of the metabolic trouble that pulls cholesterol and particle count apart.
Disagreement is not rare, and it is most common in people carrying extra weight around the middle, or with raised triglycerides and low HDL [2]. So LDL is least reliable in exactly the people who most need it to be right. If you already have other reasons to be at risk, a normal cholesterol result is the one to trust least. ApoB versus LDL cholesterol has the full comparison.
None of this makes a standard panel useless. It makes it incomplete. If you have had one and it was fine, adding ApoB costs about $37 and either confirms it or changes the picture.
A lipid panel is a snapshot, and several ordinary things move it enough to change what you conclude. Worth knowing before you act on a single result, or before you decide a reassuring one settles the matter.
None of this makes the test unreliable. It makes a single reading weaker than two, taken under conditions you can repeat. Same lab, same fasting state, same time of day.
Lp(a) is the strongest argument on this page, because the gap between who should have it and who has had it is enormous.
It is a cholesterol particle with an extra protein attached, and the amount you make is set by your genes. It barely responds to diet, exercise or statins. It is stable across your life, which means one test answers the question permanently.
Roughly 20 to 25% of people carry a raised level. In a cohort of about 71 million adults, roughly 0.1% had ever been tested [4]. One adult in four or five has it; about one in a thousand knows. As of March 2026 the American guideline agrees: the ACC, the AHA and nine other bodies now recommend measuring Lp(a) at least once in every adult, their strongest class of recommendation, and the first time a US guideline has asked for it universally. European and Canadian guidance had said the same for years.
It matters because a raised Lp(a) is not a small effect. Per particle it is substantially more atherogenic than ordinary LDL [3]. The 2026 guideline puts numbers on it: from about 125 nmol/L (50 mg/dL) risk runs roughly 1.4 times higher, and around 250 nmol/L it roughly doubles [4]. It also explains a category of case that otherwise makes no sense: the heart attack at 45 in someone lean, fit and with unremarkable cholesterol.
Nobody had a drug for it, so nobody tested it. But a drug does not have to exist for the number to be useful: it changes how hard you manage everything you can control, and it tells your siblings and children to get tested. You do not need permission to find out yours.
Some of the most useful things on this page are not on our order list at all, and two of them are not blood tests.
One blood test you may see on other heart panels is deliberately not on ours. Homocysteine does track with cardiovascular risk, but eight trials covering 37,485 people lowered it by about 25% with B vitamins and saw no fewer heart attacks, strokes or deaths [12]. So even if yours came back high, correcting it is not known to make you any safer.
Some of this is not a self-ordered panel question.
The awkward thing about heart risk is that the useful window is the one in which nothing is happening, and the tests that describe it best are the ones a routine appointment does not include. ApoB tells you how much cargo is in circulation. Lp(a) tells you what you inherited, once, permanently. If you have your numbers, seeing where each one sits against the range the evidence supports is the next thing worth doing.